DC-SIGN mediated antigen-targeting using glycan-modified liposomes: Formulation considerations
Medha Joshi(Freie Universität Berlin), Gert Storm(Yong In University), Louis van Bloois(Utrecht University), Sven C. M. Bruijns(Vrije Universiteit Amsterdam), Wendy W. J. Unger(Erasmus MC), Hakan Kalay(Amsterdam UMC Location Vrije Universiteit Amsterdam), Astrid J. van Beelen(Amsterdam UMC Location Vrije Universiteit Amsterdam), Manja Litjens(Utrecht University), Yvette van Kooyk(Amsterdam University Medical Centers)
Cited by 38
Related Papers
Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization
|Frontiers in Pharmacology|2018|937
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes
|Cancer Cell|2020|683
C-Type Lectin DC-SIGN Modulates Toll-like Receptor Signaling via Raf-1 Kinase-Dependent Acetylation of Transcription Factor NF-κB
|Immunity|2007|573
Sheddable Coatings for Long-Circulating Nanoparticles
|Pharmaceutical Research|2007|549